Clik here to view.
Travere CEO Eric Dube Named to Fortune’s LGBTQ+ Leaders List
September 19, 2024 — This week Travere president and CEO Eric Dube was named to Fortune’s inaugural list of LGBTQ+ leaders. The list features 25 executives of companies worldwide who according to...
View ArticleTravere Therapeutics Announces Voluntary Pause of Enrollment in the Phase 3...
Company to host conference call today at 4:30 p.m. ET SAN DIEGO , Sept. 26, 2024 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. , (Nasdaq: TVTX) today announced a voluntary pause of enrollment in the...
View ArticleClik here to view.
William Rote Recognized in PharmaVoice 100 Industry Leaders Reshaping the...
Tuesday, October 8, 2024 — William Rote, Ph.D., senior vice president of research and development at Travere, was named to the PharmaVoice 100 list of influential people in the life sciences. The list...
View ArticleClik here to view.
Jula Inrig Recognized in Endpoints News’ Women in Biopharma R&D, 2024
Wednesday, October 9, 2024 — Jula Inrig, M.D., chief medical officer at Travere, was named to Endpoints News 2024 Women Leaders in R&D. Each year, Endpoints News celebrates leading women who...
View ArticleTravere Therapeutics to Present Abstracts at American Society of Nephrology...
SAN DIEGO, Oct. 14, 2024 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that the Company will present 11 abstracts, including one late-breaking abstract at the upcoming...
View ArticleTravere Therapeutics and CSL Vifor Announce Swissmedic Approval of FILSPARI®...
SAN DIEGO , Oct. 17, 2024 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. , (Nasdaq: TVTX) and CSL Vifor today announced that Swissmedic has granted temporary marketing authorization for FILSPARI for the...
View ArticleTravere Therapeutics to Report Third Quarter 2024 Financial Results
SAN DIEGO , Oct. 21, 2024 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report third quarter 2024 financial results on Thursday, October 31, 2024 , before the...
View ArticleTravere Therapeutics Presents Data Reinforcing Clinical Benefit of FILSPARI®...
Nearly 60% of patients with IgAN in the SPARTAN Study achieved complete remission when using FILSPARI as first-line treatment SPARTACUS Study, PROTECT open-label extension, and real-world evidence...
View ArticleTravere Therapeutics Reports Third Quarter 2024 Financial Results
SAN DIEGO, Oct. 31, 2024 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc., (NASDAQ: TVTX) today reported its third quarter 2024 financial results and provided a corporate update. The post Travere...
View ArticleTravere Therapeutics to Present at Upcoming Investor Conferences
SAN DIEGO , Nov. 04, 2024 (GLOBE NEWSWIRE) — Travere Therapeutics, Inc. , (NASDAQ: TVTX) today announced that company management will present in the following upcoming investor conferences in November:...
View Article